Pfizer, BioNTech say Covid vaccine is more than 90% effective—’great day for science and humanity’

Business

A health worker holds blood samples during clinical trials for a Covid-19 vaccine at Research Centers of America in Hollywood, Florida, on Wednesday, Sept. 9, 2020.

Eva Marie Uzcategui | Bloomberg | Getty Images

U.S pharmaceutical giant Pfizer and German biotech firm BioNTech said their coronavirus vaccine was more than 90% effective in preventing Covid-19 among those without evidence of prior infection, according to data published Monday from their late-stage vaccine trial.

It comes as drugmakers and research centers around the world scramble to deliver a safe and effective vaccine in an attempt to bring an end to the coronavirus pandemic that has claimed over 1.25 million lives worldwide.

Scientists are hoping for a coronavirus vaccine that is at least 75% effective, while White House coronavirus advisor Dr. Anthony Fauci has previously said one that is 50% or 60% effective would be acceptable.

Albert Bourla, chairman and CEO of Pfizer, hailed the development as a “great day for science and humanity.”

The results were based on the first interim efficacy analysis conducted by an external and independent Data Monitoring Committee from the phase three clinical study. The independent group of experts oversee U.S. clinical trials to ensure the safety of participants.

The analysis evaluated 94 confirmed Covid-19 infections among the trial’s 43,538 participants. Pfizer and BioNTech said the case split between vaccinated individuals and those who received a placebo indicated a vaccine efficacy rate of above 90% at seven days after the second dose.

It means that protection from Covid-19 is achieved 28 days after the initial vaccination, which consists of a two-dose schedule.

The final vaccine efficacy percentage may vary, however, as safety and additional data continues to be collected.

“The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” Pfizer’s Bourla said in a statement.

“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen,” Bourla continued.

“With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”

Roughly 42% of the trial’s participants had diverse backgrounds, Pfizer and BioNTech said, adding that there haven’t been any serious safety concerns reported yet.

The companies said they planned to submit for emergency use authorization to the U.S. Food and Drug Administration soon after they have two months of data, which is currently on track for the third week of November.

Based on current projections, Pfizer and BioNTech expect to produce up to 50 million vaccine doses in 2020, and up to 1.3 billion doses in 2021.

The companies said they plan to submit data from the full phase three trial, which began on July 27, for scientific peer-review publication.

Products You May Like

Articles You May Like

Shareholders challenge the companies they invest in to promote good in the world
Fintech firm Revolut names former Citigroup executive Rebecca Macieira-Kaufmann to its US board
Barack Obama: ‘I am not well organized’ — 3 ways he stays productive
Thinking of putting new cash to work? Credit Suisse’s Jonathan Golub suggests waiting until after December
Winklevoss twins say bitcoin will be the decade’s best performing asset, see ’25x’ gains from here

Leave a Reply

Your email address will not be published. Required fields are marked *